As the Chief Operating Officer at Amarex Taiwan, Dr. Maggie Ho oversees operations, including APAC regulatory submissions, clinical operations, business development, and client services across the Pan Pacific region. With over 15 years of experience in clinical research and pharmaceutical product development, Dr. Ho brings a wealth of expertise to her role. Drawing on her background as a Regulatory Specialist trained in the United States, Dr. Ho excels in devising meticulous regulatory approval strategies for small molecule drugs, biologics, botanicals, and devices, navigating the complexities of product development in both the US and Asia. Her adeptness extends to offering insights into the regulatory landscapes of advanced therapies, particularly in the cell and gene therapy domains, within various markets across the US and Asia-Pacific region. Dr. Ho holds a PhD in Chemistry from Oxford University, complementing her practical experience with a solid foundation in scientific research. Her commitment to advancing knowledge in the field is underscored by presentations at esteemed institutions such as Oxford University and the Massachusetts Institute of Technology, as well as publications in prestigious journals including Nature, Nature Chemical Biology, PNAS, and PLoS Pathogen.